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Abstract
This systematic review was undertaken to determine the extent to which adult subjects representing sex
(female), race (nonwhite), and age ( > 50 years) categories are included in clinical studies of HIV curative
interventions and thus, by extension, the potential for data to be analyzed that may shed light on the influence of
such demographic variables on safety and/or efficacy. English-language publications retrieved from PubMed
and from references of retrieved papers describing clinical studies of curative interventions were read and
demographic, recruitment year, and intervention-type details were noted. Variables of interest included par-
ticipation by sex, age, and race; changes in participation rates by recruitment year; and differences in partic-
ipation by intervention type. Of 151 publications, 23% reported full demographic data of study enrollees, and
only 6% reported conducting efficacy analyses by demographic variables. Included studies recruited partici-
pants from 1991 to 2011. No study conducted safety analyses by demographic variables. The representation of
women, older people, and nonwhites did not reflect national or international burdens of HIV infection. Parti-
cipation of demographic subgroups differed by intervention type and study location. Rates of participation of
demographic groups of interest did not vary with time. Limited data suggest efficacy, particularly of early
therapy initiation followed by treatment interruption, may vary by demographic variables, in this case sex. More
data are needed to determine associations between demographic characteristics and safety/efficacy of curative
interventions. Studies should be powered to conduct such analyses and cure-relevant measures should be
standardized.
Introduction
Efforts to ‘‘cure’’ HIV—defined as either achieving astate in which the virus is controlled in the absence
of medication (sometimes called ‘‘functional cure’’) or the
disabling or removal of all replication-competent virus
(sometimes called ‘‘sterilizing cure’’)—have been active
since the 1990s. However, optimism for the potential to cure
HIV has increased since the report1 of the apparent cure of an
HIV patient in Berlin after transplantation of stem cells ho-
mozygous for the CCR5 delta-32 mutation.
The limited number of cure cases to date makes it im-
possible to know which intervention(s) will prove most ef-
fective at curing HIV, or whether effectiveness will be
equivalent across different groups of patients. Little is known
about the potential for demographic factors to affect the
safety or efficacy of curative interventions. Sex, age, or race
may influence the establishment or persistence of reservoirs
of virus that are not targeted by antiretroviral treatment
(ART) or the immune system, or efforts to disrupt them, via
differences and fluctuations in hormones, X versus Y chro-
mosome gene expression, HLA type, response to drugs [e.g.,
pharmacokinetic (PK) or pharmacodynamic (PD)], route of
acquisition of infection, duration of infection before treat-
ment initiation, immune activation/inflammation, and/or the
presence of opportunistic and/or coinfections and morbid-
ities, as outlined below.
Sex differences potentially related to cure
Clinical observations and studies have indicated that fe-
male sex is associated with lower viral load,2–6 higher CD4
count,6–8 more frequent ART side effects and discontinua-
tion,9–18 faster progression to AIDS,4,19 higher D-dimer
levels,20 greater likelihood of elite control (Steven Deeks,
personal communication), more pronounced immune and
1amfAR, The Foundation for AIDS Research, New York, New York.
2Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.
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vaccine responses,21–24 and higher immune activation.21,25–28
In vitro data, where ART exposure can be more easily con-
trolled, also suggest possible effects of sex on measures of
interest in curing HIV, including infection of and replication
in cells, transcription, and HIV promoter activity.26,28–35
Biologically based sex differences, especially in immunity,
may also arise from differential gene expression associated
with the X chromosome,19,36–39 and sex differences may also
be associated with access to or outcomes of bone marrow or
hematopoietic stem cell transplantation (HCT).40–45
Evidence suggests that a smaller persistent viral reservoir
may be associated with longer time to rebound after therapy
interruption.1,46,47 Factors determining the size of the reser-
voir may include duration of infection before ART initia-
tion48 or CD4 nadir.49 In addition to biological differences
between males and females, sociobehavioral factors (such as
access to care or level and duration of viral suppression) may
also affect these variables and thus the safety or efficacy of
curative interventions. A 2009 publication reported that in
Europe women were more likely to receive ART than men.50
A recent WHO/UNAIDS update extended this finding, by
reporting that globally, women are more likely thanmen to be
accessing ART,51 likely due largely to increased ART uptake
in antenatal care clinics. Recent data issued by the U.S. na-
tional government on the HIV continuum of care confirm that
while women have slightly higher rates than men of new HIV
diagnoses and linkage to care, women andmen are equivalent
in terms of viral suppression.52
Age differences potentially related to cure
Clinical observations indicate that older age is associated
with shorter time to death, smaller CD4 increase on ART,
lower viral load but faster viral load increase off ART, altered
PK, and increased immune activation.53–61 Older patients
may also have a decreased ability to mount immune re-
sponses against the virus.62–67 Age differences are strongly
associated with access to or outcomes of HCT.42,68–72
Sociobehavioral factors may also be important for age.
Older adults in North America are likely to present for care at
lower CD4 counts than younger adults,73 and the same is true
in Europe.74,75 According to U.S. continuum of care data,
linkage to care is lowest in young adults, but rates of viral
suppression in those aged 65 years and older compare unfa-
vorably to rates in those aged 45–64 years.52
Race differences potentially related to cure
In the context of HIV, race has been associated with dif-
ferences in plasma viral load,76,77 CD4 count,6,76 rate of CD4
decline,78 D-dimer levels,20 HLA-associated vaccine re-
sponse or viral escape,79,80 disease progression and death,81
immune and vaccine responses,82,83 and increased systemic
immune activation.84–86 Associations between race and the
function of enzymes involved in the metabolism of drugs,
including ART, have also been described.87–91 Although
HLA-B*5701 may be a better predictor of abacavir sensi-
tivity than race,92 a study in the United Kingdom demon-
strated a substantially lower prevalence of the B*5701 HLA
type in Africans compared to whites.93 Race differences in
pharmacodynamics have also been noted for responses to
therapeutic interferon-a in HIV/hepatitis C-coinfected sub-
jects.94 Results from the VaxGen trial indicated that blacks
and Asians generated higher levels of antibodies against HIV
than other participants.95
As with sex, race differences may also be associated with
access to or outcomes of bone marrow or HCT. African
Americans are less likely than whites to undergo HCT.40 In a
retrospective analysis of more than 3,000 patients who re-
ceived HCT between 1992 and 2000, black was the only race
associated with significantly higher mortality and graft-
versus-host disease (GVHD) than whites.96
Sociobehavioral differences between races have also been
observed. In this context, differences between races consid-
ered ‘‘majority’’—either numerically or, more importantly,
according to socioeconomic advantage—versus ‘‘minority/
other’’ are of particular interest. In Europe, those not of Eu-
ropean origin were more likely to present for care later.73,74
At all points along the HIV continuum of care in the United
States—particularly in new diagnoses, engagement in care,
and suppression of viral load—blacks are doing more poorly
than other races.52
Demographic predictors in hepatitis C cure
The only viral disease for which a medical ‘‘cure’’ (more
commonly referred to as sustained virological response,
SVR) is regularly attained is hepatitis C virus (HCV). Some
evidence indicates that demographic characteristics might be
associated with variable rates of SVR in HCV. A recent re-
port described treatment outcomes in older (60 years or
above) versus younger patients treated with peginterferon
alpha-2a and ribavirin. Patients in the older group had to stop
treatment more often due to virological failure and adverse
events, and were significantly less likely to reach SVR, de-
spite higher compliance and less loss to follow-up.97 Malnick
et al. (2014) reviewed several clinical trials of various HCV
treatments and found that those aged 65 years or older were
often excluded from trials, but where data were available,
older patients discontinued treatment at a higher rate and/or
achieved SVR at a lower rate than younger study partici-
pants.98
Narciso-Schiavon et al. (2010) reported that although
women had more adverse events than men, SVR rates were
similar between the sexes.99 In those receiving liver trans-
plants and experiencing HCV recurrence, SVR rates in ge-
notype 1 patients were lower in women than men.100 More
recently, the use of sofosbuvir has improved SVR rates. In the
NEUTRINO and FISSION studies, age (above or below 50
years) predicted SVR rates with different treatment combi-
nations, and while male sex and black race appeared to
be associated with lower SVR, these differences were not
significant.101
Study objectives
The National Institutes of Health (NIH), the world’s
largest single funder of clinical research, has recognized the
importance of including representatives of diverse demo-
graphics in clinical studies and requires investigators to in-
clude and examine differential effects by sex and diverse
racial and ethnic groups in studies conducted with human
subjects or on material of human origin such as tissues or
specimens.102 More recently, they have issued a policy re-
quiring researchers to balance female and male animals and
cells in preclinical research studies.103

















































Although sex, age, and race are associated with measures
thought to be important in curing HIV, via biological and/or
sociobehavioral effects, it is currently unknown whether
these demographic factors are associated with the safety or
efficacy of any curative intervention. This systematic review
was undertaken to determine the extent to which adult sub-
jects representing different sex, race, and age categories are
included in clinical studies of curative interventions and thus,
by extension, the potential for data to be analyzed that may




Clinical intervention studies for which adult males and
females were eligible, published through the end of 2013,
whose ultimate goal was to inform efforts to cure HIV either
by enhancing control of HIV in the absence of ART (i.e.,
‘‘functional cure’’ or ‘‘remission’’) and/or perturbing the
persistent viral reservoir by disabling, reducing, or removing
replication-competent virus (i.e., ‘‘sterilizing cure’’ or
‘‘eradication’’), were included.
PubMed was used to search for relevant English language
publications, and the references of retrieved papers were also
scanned. Publications were included if they involved at least
one post hoc analysis of a measure pertinent to curing HIV
(e.g., reservoir size) even if other publications referring to the
same study stated that the original intent of the study was not
cure related. To maximize the number of studies, all clinical
studies, not just those that were randomized and/or blinded
and/or controlled, were included. Case studies of single pa-
tients were not included, nor were conference abstracts. Si-
milarly, explicitly pediatric studies were excluded, but the
inclusion criteria of some included studies involved partici-
pants aged 13 years or older. One publication per study was
included in the analysis. When more than one publication
referred to a single study, the publication judged to have the
most complete demographic data was used.
Variables
Various demographic and other data were collected from
each of the analyzed publications. The total number of par-
ticipants included or enrolled into the study was noted,
without regard to whether participants received any or all of
the intended interventions or whether they were included in
analyses, as the main measure of interest for this systematic
review was to assess the access or willingness to participate,
and/or the willingness/ability of researchers to recruit, par-
ticipants who are female, older, or nonwhite. Where data
were available, the numbers of women (including male-to-
female transgender), ‘‘older’’ (defined as 50 years or over),
and nonwhite participants included were noted. Reported
analyses of safety or efficacy differences in the three demo-
graphic variables of interest were also noted.
The year in which the study started recruiting was judged
to be a more accurate indication of the timing of the study
than the year of publication because of potential variations in
time to publication. Where data were not available in the
publication, data on recruitment period were gathered on
the basis of NCT numbers (or other publications describing
the same study), when available. The country(ies) in which
the studies took place were also noted.
Cure interventions
Cure interventions were classified according to seven ca-
tegories: ATI, cell therapy, early treatment, immune modu-
lation, intensification, reactivation, and therapeutic vaccine.
ATI included studies in which ART was interrupted as an
intervention (i.e., to enhance the likelihood of viral control in
the absence of ART by, e.g., boosting immune responses), or
when it was used as a measure of the success of the inter-
vention. Treatment interruption studies in which the stated
goal was to save cost or minimize toxicities, etc. were not
included. Cell therapy included studies of gene therapy and/
or cell transplantation. Early treatment involved the initiation
of ART during a time period classified by study authors as
early in infection. Immune modulation included interven-
tions thought to enhance the function of the immune system
independently of classic vaccine responses, including agents
that affect the number or function of CD4, CD8, or other
immune cells. Intensification was defined as the addition of
ART agents beyond standard medical practice. Reactivation
studies employed agents such as histone deacetylase inhibi-
tors (and other drug classes) aimed at increasing transcription
from proviral DNA. Therapeutic vaccine studies employed
vaccines aimed at stimulating the host immune system to
generate more effective cellular and/or humoral control of
existing infection. Single studies that included more than one
category of intervention were assigned to each of the cate-
gories described in the study.
Statistical analyses
Statistical analyses were performed using SPSS (Version
19.0, IBM Corp., Armonk, NY). Trends across time and
differences across interventions were investigated using a
general linear model (GLM). Linear regression was used to
determine trends across time, with recruitment year (1991–
2008) coded as a continuous variable, beginning at zero (year
1991). Linear models were fit to enable detection of in-
creasing or decreasing trends and quadratic models (which
included the linear term) were fit to detect curvilinear trends.
To determine differences across interventions, one-way ana-
lyses of variance (ANOVA) were used with intervention type
as the independent variable. The remaining analyses were
conducted using nonparametric tests. To determine differences
in sex and nonwhite participation in interventions, one-sample
binomial z-tests were conducted using the proportion of total
subjects per intervention as the expected value and proportion
of women or nonwhites as the observed value. Differences
across countries were investigated with Pearson Chi-square
tests. For comparisons across the seven interventions, type I
error was controlled using a Bonferroni-corrected threshold to
establish significance (0.05/7= 0.007). For all other compari-
sons, significance was established at a < 0.05.
Results
General
In all, 151 publications were retrieved describing 159
studies that were judged nonduplicative. (Six publications
described two studies and one publication described three

















































studies.) Studies were published between 1995 and 2013.
Recruitment periods were available for 76 publications,
with start dates ranging from 1991 to 2011. Time from start
of recruitment to publication ranged from 0 to 13 years
(mean 5.7, median 5). The 159 studies included a total
of 14,345 participants. The number of participants per
study ranged from 2 to 4,111 (mean 94, median 25). Each
study included 1–3 (mean 1.3, median 1) interventions
(e.g., patients were treated early in infection, then admin-
istered a therapeutic vaccine, followed by a treatment
interruption).
The 137 studies conducted within single countries took
place in Argentina (1), Australia (4), Belgium (2), Brazil (2),
Canada (4), Denmark (1), France (16), Germany (6), Hun-
gary (1), Italy (5), Japan (1), Netherlands (4), Norway (1),
Spain (11), Sweden (4), Switzerland (1), Thailand (2), United
Kingdom (4), and the United States (67). Table 1 provides an
overview of publications and studies by intervention, de-
mographics, and number of study countries.
Interventions
Of the 14,345 participants in clinical studies, fewer than
1% joined reactivation studies, whereas over 50% were in-
cluded in immune modification studies. More data are shown
in Table 2. While the average number of participants in each
type of intervention variedwidely (Fig. 1), a one-wayANOVA
found that differences across all seven intervention types
were not significant (F6,198 = 1.0, p = 0.403). This is likely due
to broad intraintervention variability.
In terms of the number of participants, Intensification
(R2 = 0.277, df = 1,16, p = 0.025) and Tx vaccine (R2 = 0.237,
df = 1,16, p = 0.041) showed linear increases from 1991 to
2008, whereas ATI (R2 = 0.552, df= 2,15, p = 0.002) and
Immune Mod (R2 = 0.403, df= 2,15, p= 0.021) showed qua-
dratic trajectories. However, only the trajectory for ATI
passed threshold for multiple comparisons (a = 0.007).
Studies of Early tx, Cell tx, and Reactivation interventions
did not change over time ( ps> 0.21). To visualize these effects,
Table 1. Overview of Publications and Studies by Demographics,
Intervention Type, and Study Countries
Number of
publications
(of 151) % publications
Number of
studies
(of 159)a % studies
Interventionb
Early treatment 34 22.5 37 23.3
Cell therapy 17 11.3 17 10.7
Immune modification 38 25.2 42 26.4
Treatment intensification 18 11.9 19 11.9
Reactivation 6 4.0 6 3.8
Treatment interruptionc 51 33.8 54 34.0
Therapeutic vaccine 40 26.5 41 25.8
Demographics
Women
Insufficient data 32 21.2 34 21.4
None 32 21.2 32 20.1
At least 1 participant 87 57.6 93 58.5
Olderd
Insufficient data 56 37.1 61 38.4
None 21 13.9 21 13.2
At least 1 participant 74 49.0 77 48.4
Nonwhite
Insufficient data 105 69.5 112 70.4
None 4 2.6 4 2.5
At least 1 participant 42 27.8 43 27.0
Number of demographic variables reportede
0 25 16.6 27 17.0
1 27 17.9 29 18.2
2 64 42.4 68 42.8
3 35 23.2 35 22.0
Study country
Single 133 88.1 137 86.2
Multiple 14 9.3 16 10.1
No data 4 2.6 6 3.8
aNumber of studies is greater than number of publications because six publications reported on two studies and one publication reported
on three studies.
bInterventions do not add up to total numbers of publications and studies because many publications and studies included more than one
type of study.
cIncluded studies where treatment interruption was an intervention or was used to evaluate success of an intervention.
dDefined as 50+ years of age.
eAmong: number of women; whether included participants 50 + years old; number of nonwhite race.

















































years were divided into three epochs: pre-cART (up to and
including 1995), triple cART (1996–2002), and multi-cART
(2003–2008). A fourth epoch, post-Berlin patient (2009–
present), was not included in analyses as there were too few
studies retrieved (consistent with the observation that the mean
time from recruitment to publishing was 5.7 years). As Fig. 2
illustrates, recruitment into ATI and ImmuneMod intervention
studies peaked during the triple-cART epoch, whereas re-
cruitment into Intensification and Tx vaccine studies continued
to increase over epochs into the multi-cART epoch.
Demographics—general
Of 151 publications, 23% provided some detail of the
demographics of participants on all three measures—sex,
inclusion of older participants, and race; 42% of publications
provided details on two demographic variables, 18% pro-
vided details on one demographic variable, and the remaining
17% of publications provided no demographic details (see
Table 1). No study reported conducting analyses of safety/
adverse event outcomes by any of the demographic variables
investigated in this systematic review. There were no sig-
nificant differences in the number of demographic variables
reported across intervention types (F6,190 = 0.8, p = 0.609),
nor were there linear (R2 = 0.158, df = 1,16, p= 0.102) or
quadratic (R2 = 0.163, df= 2,15, p = 0.264) changes across the
timeframe of 1991 to 2008.
Sex
Data on the sex of participants were available in 119 (79%)
of 151 publications, 125 of 159 (79%) studies. Of the 12,946
participants in those studies, 2,323 (17.9%) were women. The
percentage of women in the studies ranged from 0 to 89%
(mean 14%, median 11%). Of the 125 studies where sex data
were available, 32 (26%) reported no women in the study. A
total of 140 publications described studies conducted entirely
within (n= 65) or entirely outside (n = 75) the United States.
There was a trend for publications reporting zero women, or
where the number of women was not reported, to be con-
ducted in the United States (v2 = 3.2, p = 0.075; United States
34/65, outside 28/75; Fig. 3).
Of the 2,323 women included in studies, fewer than 1%
participated in cell therapy or reactivation studies. More than
50% of all female participants took part in studies of immune
modulation. Compared with all participants, women were
less likely to take part in Early tx (z = 4.85, p < 0.001), Cell tx
(z = 3.76, p < 0.001), Intensification (z = 4.48, p < 0.001), and















Early treatment 3,285 34 5 (5) 8 (23)
Cell therapy 245 8 0 (5) 4 (9)
Immune modulation 7,516 30 5 (10) 7 (30)
Treatment intensification 394 13 1 (2) 13 (14)
Reactivation 113 11 3 (1) n/a (6)
Treatment interruption 4,566 40 7 (9) 14 (36)
Therapeutic vaccine 2,381 36 3 (8) 5 (24)
FIG. 1. Mean number of participants in each type of in-
tervention. Error bars indicate – 1 standard error.
FIG. 2. Number of studies of each intervention type by
epoch. The recruitment year variable was divided into four
epochs: pre-combination antiretroviral therapy (cART) (up
to and including 1995), triple cART (1996–2002), multi-
cART (2003–2008), and post-Berlin patient (2009–present).
The most recent epoch was not included in this analysis as
there were too few studies included in this review. *p < 0.05,
**p < 0.007.

















































Tx vaccine (z = 5.23, p < 0.001) interventions and were more
likely to be in Immune mod (z = 3.53, p < 0.001) and ATI
(z = 5.82, p < 0.001) interventions. All survive correction for
multiple comparisons (a= 0.007). There was no difference
for Reactivation (z = 1.04, p = 0.298) intervention studies
(Fig. 4).
As a median percentage of all participants in each inter-
vention type, studies of immune modulation and reactivation
recruited the greatest number of women, while cell therapy
studies recruited the fewest. There were no significant dif-
ferences in percentage of woman participants across inter-
vention type (F6,158 = 1.1, p = 0.356, Fig. 5A). However,
exploratory independent sample t-tests show differences
between intervention types (Fig. 5B). More data are shown in
Table 2.
There were no significant linear (R2 = 0.050, df = 1,16,
p = 0.372) or quadratic (R2 = 0.171, df = 2,15, p = 0.245)
changes in percentage of women participants from 1991 to
2008.
In all, 87 (57.6%) publications reported including at least
one woman. Of these, seven (8%) reported conducting sex
difference analyses, of which two reported that there were
significant sex differences in efficacy outcomes.
Age
Data on the inclusion of participants aged 50 years or older
were available in 95 (63%) of 151 publications, 98 (62%) of
159 studies. The number of older participants was available
for only 45 publications and studies. Of these, 21 publications
and studies reported no older participants. The percentage of
older participants ranged from 0 to 60 (mean 13.4, median
8.3). A total of 49 publications (52 studies) reported that
participants aged 50 years or older were included, but not
how many. Six publications (seven studies) reported con-
ducting age difference analyses, and no differences were
found.
Because only 24 publications and studies reported the
number of older participants (n = 72), no further analyses
were conducted on this variable.
FIG. 3. Participation of women and nonwhites in studies
conducted entirely within or outside the United States.
+p< 0.08, **p < 0.001.
FIG. 4. Sex differences in participation by intervention.
One-sample binomial z-tests were conducted using the
proportion of total subjects per intervention as the expected
value (black bars) and proportion of women as the observed
value (gray bars). Proportions are represented as percent-
ages. **p < 0.007.
FIG. 5. (A) Mean percentage of women recruited into
each type of intervention. Error bars indicate – 1 standard
error. Lines indicate significant (at p < 0.05) differences
between interventions from pairwise t-tests. (B) p-values of
pairwise t-tests showing differences between interventions
in the mean percentage of women participants. *p < 0.05,
**p < 0.007.


















































Data on the number of nonwhite participants included in
studies were available in 46 (30%) of 151 publications, 47 of
159 (30%) studies. Of the 8,074 participants in those studies,
1,904 (23.6%) were nonwhite. The percentage of nonwhites
in studies ranged from 0 to 60% (mean 25.5%, median 23%).
Of the 47 studies where nonwhite data were available, four
(8.5%) reported no nonwhites in the study. A total of 140
publications described studies conducted entirely within
(n = 65) or entirely outside (n = 75) the United States. Pub-
lications reporting zero nonwhites, or where the number of
nonwhites was not reported, were less likely to be conducted
in the United States than outside the United States (v2 = 12.7,
p < 0.001; United States 38/65, outside 64/75; Fig. 3).
Of the 1,904 nonwhite participants included in studies,
none was included in reactivation studies, while more than
70% took part in studies of immune modulation. Compared
with all participants, nonwhites were less likely to take part in
Early tx (z = 9.32, p< 0.001), ATI (z = 9.98, p < 0.001), and Tx
vaccine (z = 7.27, p< 0.001) and more likely to be in Cell tx
(z = 2.85, p = 0.004) and Immune mod (z = 20.45, p < 0.001)
intervention studies (Fig. 6). All survive correction for mul-
tiple comparisons (a= 0.007). There was no difference for
Intensification (z= 0.44, p = 0.660).
As a median percentage of all participants in each inter-
vention type, studies of treatment intensification and treat-
ment interruption recruited the greatest number of nonwhite
participants, while reactivation studies recruited none.
Among the six intervention types that did recruit nonwhite
participants, there were no significant differences in the
percentage of nonwhite participants across intervention type
(F5,57 = 0.2, p = 0.943; Fig. 7). Furthermore, exploratory in-
dependent sample t-tests did not reveal differences between
intervention types ( ps > 0.21). More data are shown in Table
2. Included in these data are two studies (one Early tx and one
Tx Vaccine) that had 100% nonwhite participants: one was
conducted in Thailand and the other in Japan (in which all
subjects were either Thai or Japanese, respectively). Because
the aim of this review was to identify the rate at which sub-
jects considered ‘‘minority’’ are recruited into studies, we
conducted the analyses without these studies and the results
did not change (ANOVA: F5,55 = 0.9, p = 0.497; t-tests:
ps> 0.24).
There were no significant linear (R2 = 0.051, df= 1,14,
p = 0.403) or quadratic (R2 = 0.180, df = 2,13, p = 0.276)
changes in percentage of nonwhite participants from 1991 to
2008. Two (1.3%) publications/three (1.9%) studies reported
conducting race difference analyses, and no differences were
found.
Although it would have been interesting to conduct an
interaction analysis to test whether combinations of demo-
graphic characteristics were associated with any of the vari-
ables of interest, almost no publications provided demographic
data in sufficient detail to allow such an analysis.
Discussion
Recruitment into clinical studies
Of adults living with HIV in the United States in 2010,
33% were female, 67% were nonwhite,104 and 19% were
older than 55 years.105 Worldwide, women account for 50%
of all those living with HIV,106 older adults constitute
10%,107 and 85% are living in regions of the world where
white is not the predominant race.108 Despite the populations
in which HIV infection is prevalent, and funder policies re-
quiring representative participation in clinical studies,102 this
systematic review suggests that participation in cure studies
does not accurately reflect national or international burdens
of infection in women, older adults, or nonwhites.
If the safety and efficacy profiles of curative interventions
were known to be equivalent across different demographic
groups, it may not be as important that studies are conducted
largely in young white males. However, this systematic re-
view reveals that the current data are insufficient to draw this
conclusion. It is currently believed that an HIV cure may
initially be more feasible in those whose virus is well
FIG. 6. Race differences in participation by intervention.
One-sample binomial z-tests were conducted using the
proportion of total subjects per intervention as the expected
value (black bars) and proportion of nonwhites as the ob-
served value (gray bars). Proportions are represented as
percentages. **p < 0.007.
FIG. 7. Mean percentage of nonwhites recruited into each
type of intervention. Error bars indicate – 1 standard error.
No nonwhites were reported as participants in reactivation
interventions. Pairwise t-tests revealed no significant dif-
ferences between interventions.

















































suppressed. In the United States, this tends to be found more
often in whites, equally in males and females, and more often
in those aged 55–64 years.52 The GRACE (gender, race, and
clinical experience) trial demonstrated that it is possible to
recruit women and racial minorities into HIV clinical re-
search.109 At this relatively preliminary time in the devel-
opment of curative strategies, it will be crucial to determine if
differences associated with demographics exist.
Are there demographic differences?
Although many data points were missing in the current
review, making broader generalizations difficult, some in-
teresting observations emerged. Two publications noted sex
differences in intervention efficacy, and both were studies of
early treatment followed by treatment interruption. Des-
quilbet et al. (2004) described 58 patients, including 13
women, in the French PRIMO cohort who started therapy
during acute (none or one Western blot band) or early (two or
more Western blot bands) infection. There was a median 1.5
years of viral suppression before patients elected to stop
therapy for various reasons. At 12 months postinterruption,
women had significantly lower viral loads (by a log) than
men. As previously described in other studies, women also
had lower baseline viral loads, but even when adjusted for
baseline viral load, women still had lower off-therapy viral
loads.110 Hoen et al. (2005) conducted the PRIMSTOP study,
also in France, in 26 patients (five women) who initiated ART
(plus hydroxyurea) for 34 weeks during primary infection
(three or fewer Western blot bands), followed by alternating
periods of treatment interruption and ART. In a multivariate
analysis, female sex was the only variable that predicted vi-
rological success (defined as VL< 1,000) 6 months after ART
discontinuation. Virological success was also associated with
greater gains in CD4 T cells. As in other studies, these authors
noted that women also started with lower baseline viral
loads.111
Replicating these studies of early treatment in women in
other settings may prove challenging. It is commonly be-
lieved that women are rarely diagnosed and treated during
early infection, although national data confirming this appear
to be lacking. However, data from cohorts and studies indi-
cate that such women are in fact available. Data from the
Duke-UNC Acute HIV Infection Research Consortium in-
dicate that 12% of the cohort is female,112 somewhat lower
than the 22% of HIV cases in females in North Carolina in
2012.113 Similarly, the primary infection Options cohort in
San Francisco consists of about 4% women,114 reflecting the
low contribution (about 8%115) of women to that city’s epi-
demic. However, a 2006 publication116 reported that 33% of
patients who enrolled in the Acute Infection and Early Dis-
ease Research Program (AIEDRP) at the site in Baltimore,
Maryland were female, close to the 35% of all HIV cases in
Baltimore in 2014.117 In France, in the PRIMO cohort con-
sisting of 1,267 patients enrolled during primary HIV infec-
tion, 16% were women,118 lower than the national 29% of all
HIV cases.119 Although not necessarily reflective of national
averages, the SPARTAC trial conducted across eight coun-
tries (United Kingdom, South Africa, Brazil, Uganda, Spain,
Australia, Italy, and Ireland) consisted of a cohort of 371
subjects identified during primary infection, of whom 40%
were women.120
It is possible that some combination of demographic var-
iables may also have been associated with participation or
efficacy. For example, it may be possible that a certain in-
tervention is more efficacious in black females, or that older
males are more or less likely to participate in studies than
other subjects. Study subjects can be described by, and em-
body the characteristics of, multiple demographic and other
descriptors. Data available in the publications described in
this review did not often enough provide the level of detail
that would be required to conduct such analyses.
Factors associated with participation
of underrepresented groups
Historically, women, older people, and nonwhites have
been underrepresented in HIV clinical studies121–123 and
many reasons for this have been invoked, ranging from
medical mistrust to poverty to childcare and employment
challenges.124–126 In addition, care provider attitudes toward
and perceptions of female, older, and nonwhite patients also
tend to be more negative,127–129 which may negatively in-
fluence the likelihood of solicitation into clinical research.
Taking these factors together, it is perhaps not surprising that
women, older people, and nonwhites are underrepresented in
HIV cure-related clinical studies. Despite NIH guidelines,
there was a tendency for publications reporting zero female
participants, or where the number of women was not re-
ported, to be conducted more often inside than outside the
United States. However, studies including nonwhites were
significantly more likely to take place inside the United States
than outside. The participation of these two groups in clinical
studies of cure interventions has not changed in the period
1991–2008.
It should be noted that it is conceivable that some studies
may be relevant only to circumscribed populations. In an
attempt to correct for this bias, this study undertook to review
only those studies for which both men and women were el-
igible. However, there may be limitations, such as CCR5
genotype, that might guide the exclusion of some types of
patients, especially nonwhites, in whom the delta-32 allele
would not be expected to be present.130
It is interesting to note that women and nonwhites are more
and/or less likely than participants overall to take part in
certain types of cure studies. Women and nonwhites were
both more likely to take part in immune modulation studies
when compared to all participants. It is difficult to know
whether such studies are more appealing to these participants
or if so, why. From the opposite perspective, immune mod-
ulation and reactivation studies had a greater percentage of
women included than other types of studies, while studies of
treatment intensification and treatment interruption recruited
more nonwhites than did other types of studies. Again, it is
difficult to understand the differences in the motivations or
behaviors of the researchers recruiting participants to these
studies.
It is possible to speculate that physicians or health care
providers serving as a link between these populations and
different types of cure studies may make assumptions about
health literacy or self-efficacy associated with sex or race and
that these assumptions may either guide the ways in which
they present studies to potential participants (leading to dif-
ferences in the appeal of various kinds of studies) or the

















































extent/range of efforts they employ to recruit such partici-
pants (leading to differences in percentage participation). For
reasons that would be more difficult to understand, there may
also be systematic differences between study types in meth-
ods or locations of advertising and recruitment efforts (e.g.,
inner city clinics versus college campuses). There was no
apparent relationship between the geographic location of
particular study types, either between or within countries, and
the likelihood of inclusion of women or nonwhites.
Potential to generate data on demographics
Despite the general paucity of analyses by demographics
in this dataset, it may nonetheless be possible—with access to
the raw data—to conduct post hoc analyses (ormeta-analyses),
even if only descriptive (especially in those studies with in-
sufficient participant numbers to conduct formal analyses).
Many of the studies in this dataset anecdotally described
unusual safety or efficacy outcomes, but rarely provided
demographic data of those participants. It is remarkable that
no studies conducted analyses by demographics on safety
outcomes.
Analyses of biomedical outcomes according to demo-
graphic variables can be challenging to interpret. Sex, al-
though arguably the most clear-cut of the three demographic
variables investigated here because of its categorical nature,
can be complicated by age (e.g., premenopausal versus
postmenopausal) and/or the use of hormonal contraceptives.
For this systematic review, 50 years of age was chosen as a
cut-off for ‘‘older’’ participants, to mirror many epidemio-
logical reports. However, age is a continuous variable with no
major biological differences expected in relevant measures in
individuals close to the cut-off on each side. Age may also
have very different associations with outcomes depending on
whether the participant acquired HIV at a younger age and
has aged with the virus, or whether the virus was acquired in
older age. Race is potentially the most complicated of these
variables. For these analyses, white vs. nonwhite was chosen
as the comparator, but there is little a priori reason not to
choose some other category demarcation, for example, black
vs. nonblack. In fact, more genetic variation among blacks
has been reported than among all other races,131 so the latter
analysis may have more biological relevance.
In the context of biomedical HIV research, HLA may be
better related to safety and/or efficacy than race, especially
for interventions that require an immune response associated
with particular HLA types. However, reporting the race of
participants would still provide a useful indicator of the ac-
cess to or willingness to participate in cure studies. To con-
duct such analyses, participants representing each of these
demographics will need to be recruited to studies in adequate
numbers. Investigators interested in probing the associations
between demographic variables and safety or efficacy will
face many challenges.
Limitations
Although steps were taken to identify duplicates, we can-
not rule out the possibility that some publications described
studies that were at least partially overlapping with others,
and as such some participant groups may be overrepresented.
There may also be other publications describing studies that
fit the inclusion criteria that we did not identify, possibly
resulting in underrepresentation of other participant groups.
In addition, it is possible that in cases where single studies
were described in multiple publications, the publications not
included in this systematic review may have included de-
mographic analyses that were not identified, although efforts
were made to minimize this. Finally, identifying clinical
studies that fit the stated cure definition was in many cases a
judgment call, and others may have classified the included
and excluded publications differently.
One of the greatest limitations of this systematic review
was the lack of data concerning some key variables. Data on
the number of women, older people, and nonwhites were
missing for 21%, 84%, and 70% of publications, respectively,
limiting our ability to analyze the associations between these
variables and participation in studies of different interven-
tions over time. In some studies where these demographics
were reported, no participants in those categories were in-
cluded, further limiting the analysis. In addition, the year in
which recruitment started was available for only 50% of
publications. Despite these limitations, significant differ-
ences were still found on a number of measures. It is not
possible to know whether the results reported in this sys-
tematic review would change if these data were available.
Recommendations
Several recommendations emerge from this study: (1)
study authors should report at least basic (sex, age, race)
demographic data of those who enroll into studies and those
whose data are analyzed; (2) outcomes—both safety and
efficacy—should be analyzed by demographic variables and
results of such analyses should be reported; (3) to the extent
possible, studies should be powered to explore demographic
differences; (4) when studies are not sufficiently powered to
allow such analyses, meta-analyses among similar interven-
tions may provide important information; (5) to facilitate
such meta-analyses, standardized endpoint measures should
be taken, including, for example, changes in viral load, CD4
count, and proviral DNA, at a minimum; and (6) animal
studies may provide preliminary indications of potential de-
mographic differences, at least concerning sex and age.
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